UPDATE 1-Celgene's Revlimid shines, revenue beats estimates

Oct 27 (Reuters) - U.S. biotechnology company Celgene Corp raised its profit and revenue forecast for the year and posted third-quarter results that beat Wall Street estimates, lifted by higher demand for its flagship multiple myeloma drug, Revlimid.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.